AACR 2024 preview – “cancer vaccines” primed to underwhelm
Projects from the likes of BioNTech, Transgene and Scancell will feature, but still have much to prove.
Will the tills ring for Iovance?
The group has approval for Amtagvi, but now faces the prospect of a solo launch.
Another setback for Opdualag's post-melanoma plan
The latest failure, in colorectal cancer, follows a recent disappointment in second-line liver.
Moderna moves on swiftly with its neoantigen immunotherapy
Lung cancer will soon join melanoma as a phase 3 indication for mRNA-4157, an asset Merck & Co last year endorsed to the tune of $250m.
Immatics builds on its PRAME success
PRAME has become a hot target for Immatics, which is now clinically progressing two different modalities against this antigen.
ASCO 2023 – in Lag3 Regeneron could beat Bristol Myers Squibb
Regeneron’s fianlimab could be biopharma’s most potent Lag3 project, and has shown activity in a new melanoma setting
